



ADULT MEDICATION GUIDELINE

DOMPERIDONE

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and
Breastfeeding](#)

Restrictions

[Formulary: Unrestricted](#)

Medication Class

Dopamine antagonists

Presentation

Form: 10mg tablet

Storage

Store at room temperature, below 25°C

Dose

Stimulation of lactation

Oral:

10mg three times a day, maximum 60mg/day

Consider tapering dose slowly when ceasing, to minimise disruption to milk supply. Avoid discontinuing abruptly.

Nausea and Vomiting

Oral:

10mg three times a day, for up to 1 week

Gastroparesis

Oral:

10mg three times a day, for up to 4 weeks.

Administration

To be taken at least 30 minutes before meals if used for Gastroparesis

Monitoring

Domperidone may increase QT interval. Risk is greater in doses >30mg/day and patients older than 60 years of age.

When used for lactation:

- Screen mothers for past history of cardiac arrhythmias or use of drugs that prolong the QT interval; refer to the Australian Medicines Handbook for [Drugs that may prolong QT interval](#)
- Consider an ECG for women of concern before commencement of domperidone and at 48 hours. If there is prolongation of the QTc interval, domperidone should be ceased.

Pregnancy

1st Trimester: consider alternative

2nd Trimester: consider alternative

3rd Trimester: consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Considered safe to use

Comments

Avoid use in women with underlying cardiac diseases and pre-existing prolongation of QT interval.

Domperidone is contraindicated in moderate and severe hepatic impairment.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Newborn Feeding and Maternal Lactation Clinical Guidelines [Newborn Feeding & Maternal Lactation Guidelines](#)

WNHS Clinical Guideline: O&G: [Management of Mastitis and abscess](#)

WNHS Patient Information Leaflet: [Domperidone to increase milk supply](#)

References

Australian Medicines Handbook. Domperidone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 27 Apr] Available from: <http://amhonline.net.au>

The Royal Women's Hospital. Domperidone. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2022 April 27]. Available from: <https://thewomenspbmg.org.au/medicines/domperidone/>

U.S. National Library of Medicine. Oxytocin. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): U.S. National Library of Medicine; 2021 [cited 2022 Apr 27]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501371/>

The Royal Women's Hospital. Health Information. Breastfeeding Problems. Low Milk Supply. Domperidone; 2019 [updated 2019 Feb 19; cited 2022 April 27]. Available from: <https://thewomens.r.worldssl.net/images/uploads/fact-sheets/Domperidone-for-increasing-breast-milk-supply-260219.pdf>

APILAM: association for promotion and cultural and scientific research of breastfeeding. Domperidone E-lactancia [Internet]. 2002 [updated 2021 Jun 21; cited 2022 April 27]. Available from: <https://www.e-lactancia.org/breastfeeding/domperidone/product/>

Keywords	Domperidone, Motilium, low milk supply, lactation, lactation stimulation, breastfeeding, lactation problem, increased milk supply				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	Dec 2014	Last Reviewed:	27/04/2022	Review Date:	27/04/2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	07/06/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.